Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Biohaven Pharmaceutical Holding Co Ltd Market Cap
Based on ratings from 5 stock analysts, the Biohaven Pharmaceutical Holding Co Ltd stock price is expected to increase by 27.14% in 12 months. This is calculated by using the average 12-month stock price forecast for Biohaven Pharmaceutical Holding Co Ltd. The lowest target is $54 and the highest is $76. Please note analyst price targets are not guaranteed and could be missed completely.
BHVN is a stock in Healthcare which has been forecasted to be worth $61.75 as an average. On the higher end, the forecast price is $76 USD by from Morgan Stanley and on the lower end BHVN is forecasted to be $54 by Ashwani Verma from UBS.
These are the latest 20 analyst ratings of BHVN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Gerberry B of A Securities | Buy | $62 | Maintains | Sep 24, 2024 |
| William Pickering Bernstein | Outperform | $66 | Maintains | Sep 24, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $59 | Reiterates | Sep 24, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Sep 24, 2024 | |
| Leonid Timashev RBC Capital | Outperform | $68 | Maintains | Sep 24, 2024 |
| Brian Skorney Baird | Outperform | $60 | Maintains | Sep 23, 2024 |
| Marc Goodman Leerink Partners | Outperform | $60 | Maintains | Sep 23, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $76 | Maintains | Sep 23, 2024 |
| Amy Li Jefferies | Buy | $57 | Initiates | Sep 16, 2024 |
| Leonid Timashev RBC Capital | Outperform | $59 | Reiterates | Sep 4, 2024 |
| William Pickering Bernstein | Outperform | $55 | Initiates | Sep 4, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Aug 19, 2024 | |
| Ashwani Verma UBS | Buy | $54 | Maintains | Aug 13, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Aug 12, 2024 | |
| Terence Flynn Morgan Stanley | Overweight | $58 | Initiates | Jul 24, 2024 |
| Leonid Timashev RBC Capital | Outperform | $59 | Reiterates | Jun 18, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | May 30, 2024 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $59 | Reiterates | May 30, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $59 | Maintains | May 13, 2024 |
| Ashwani Verma UBS | Buy | $60 | Maintains | Apr 23, 2024 |
When did it IPO
2017
Staff Count
239
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Vladimir Coric M.D.
Market Cap
$4.59B
In 2023, BHVN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BHVN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Biohaven has successfully met the primary objective in a study assessing its drug for a genetic brain disorder, according to a company announcement.
Why It Matters - Biohaven's successful study indicates potential for a new treatment, which could boost revenue prospects, enhance market position, and attract investor interest in the biotech sector.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Investopedia
Summary - Biohaven (BHVN) shares rose 15% following positive study results for its experimental treatment targeting a rare neurological condition.
Why It Matters - Positive study results can indicate strong future revenue potential, driving investor confidence and stock performance, which can lead to increased interest and investment in Biohaven.
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - Biohaven stock rose after positive results for its experimental drug that demonstrated slowed progression in a rare disease lacking approved treatments.
Why It Matters - Biohaven's stock surge indicates strong market confidence in its drug's potential, signaling growth prospects and increased value for investors in a high-demand therapeutic area.
Tue, 24 Sep 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - Biohaven Ltd. (NYSE: BHVN) announced positive Phase 3 clinical trial results for troriluzole, aimed at treating spinocerebellar ataxia (SCA), boosting its prominence in the biopharmaceutical sector.
Why It Matters - Positive Phase 3 trial results for Biohaven's drug could boost stock prices, attract investment, and indicate potential market success, signaling growth opportunities in the biopharmaceutical sector.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Biohaven Ltd. (BHVN) announced topline results from Study BHV4157-206-RWE, showing the efficacy of troriluzole after three years in improving mean f-SARA scores.
Why It Matters - The positive results from Biohaven's pivotal study on troriluzole suggest strong long-term efficacy, potentially enhancing the company's market position and attracting investor interest.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Market Watch
Summary - Biohaven shares rose 13% in premarket trading after announcing positive results from a clinical trial for its treatment of a rare neurological disorder.
Why It Matters - Biohaven's treatment success boosts investor confidence, indicating potential revenue growth and market value increase, reflecting positively on future stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
